Elsevier

Biochemical Pharmacology

Volume 71, Issue 5, 28 February 2006, Pages 646-656
Biochemical Pharmacology

Niacin induces PPARγ expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways

https://doi.org/10.1016/j.bcp.2005.11.019Get rights and content

Abstract

HM74 and HM74a have been identified as receptors for niacin. HM74a mediates the pharmacological anti-lipolytic effects of niacin in adipocytes by reducing intracellular cyclic AMP (cAMP) and inhibiting release of free fatty acids into the circulation. In macrophages, niacin induces peroxisome proliferator-activated receptor γ (PPARγ)-dependent and cAMP-dependent expression of genes mediating reverse cholesterol transport, although via an unidentified receptor. We describe constitutive expression of HM74a mRNA and hypoxia- and IFNγ-inducible expression of HM74 and HM74a in human monocytic cell lines and primary cells in culture. In U937 cells niacin-induced expression of 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), the most potent endogenous ligand of PPARγ. Both niacin and the structurally distinct HM74/HM74a ligand acifran-induced nuclear expression of PPARγ protein and enhanced PPARγ transcriptional activity. Niacin-induced PPARγ transcriptional activity was pertussis toxin sensitive and required activity of phospholipase A2 (EC 3.1.1.4), cyclo-oxygenase (EC 1.14.99.1) and prostaglandin D2 synthase (EC 5.3.99.2). Niacin also induced PPARγ transcriptional activity in HM74 and HM74a CHO cell transfectants, although not in vector-only control cells. This was sensitive to pertussis toxin and to inhibition of phoshoplipase A2 and cyclo-oxygenase activity. Additionally, niacin increased intracellular cAMP in U937 via a pertussis toxin and cyclo-oxygenase-sensitive mechanism. These results indicate that HM74 and HM74a can mediate macrophage responses to niacin via activation of the prostaglandin synthesis pathway and induction and activation of PPARγ. This suggests a novel mechanism(s) mediating the clinical effects of pharmacological doses of niacin.

Introduction

HM74 (GPR109B, GenBank accession no. NM_006018) and HM74a (GPR109A, GenBank accession no. NM_177551) are highly homologous Gi-G-protein-coupled receptors that were initially identified as receptors for niacin (nicotinic acid, Vitamin B3) [1], [2], [3]. HM74a, the human homologue of murine PUMA-G (protein upregulated in macrophages by IFN-γ[4]), is the higher affinity receptor with niacin binding and G-protein activation evident at 0.05–1 μM Kd/EC50[1], [2], [3]. HM74 has 96% nucleotide sequence identity and 89% amino acid identity with HM74a, encompassing 7 predicted amino acid changes and a 24 amino acid C-terminal extension [2], [5]. These changes are sufficient to give HM74 much reduced affinity for niacin, with ligand binding and G-protein activation generally described as non-saturable [1], [2].

Despite the significantly higher affinity of niacin for HM74a than HM74, it is unlikely that it represents the endogenous ligand for either receptor [6]. However, HM74a might mediate the pharmacological anti-lipolytic effects of niacin, which can be achieved at plasma concentrations ≥4 μM [6]. The mechanism of niacin's anti-lipolytic effect is thought to involve an inhibitory G-protein signal that reduces production of adipocyte cyclic AMP (cAMP) via adenylyl cyclase and so reduces hormone-sensitive lipase activity due to reduced protein kinase A activation [6], [7]. This inhibits release of free fatty acids (FFA) from adipose tissue into the circulation, resulting in a 15–35% increase in hepatic secretion of high density lipoprotein (HDL) and a 5–25% decrease in low density lipoprotein (LDL), the primary target for cholesterol-lowering treatment to reduce both the risk of and mortality due to coronary heart disease [7], [8]. That HM74a might mediate this effect is supported by niacin-induced reduction of intracellular cAMP in HM74a-transfected CHO-K1 [3], 293EBNA [1], HEK293 and 3T3L1 adipocytes [9]. Additionally, experiments in PUMA-G-deficient mice demonstrated 75% reduction in niacin binding to adipocyte membranes associated with loss of niacin-induced inhibition of FFA release [3].

The observation that the fatty acid-derived ketone body (d)-β-hydroxybutarate ((d)-β-OHB) mediates similar anti-lipolytic effects to niacin with respect to reduction of serum FFA [10], [11] and inhibition of adipocyte lipolysis [12] recently led to the identification of (d)-β-OHB as the first endogenous ligand for HM74a [13]. (d)-β-OHB suppressed FFA efflux from murine adipocytes in a PUMA-G-dependent manner and induced [35S]GTPγS binding to membranes from HM74a and PUMA-G transfectants with an EC50 of 0.8 mM [13]. This is within the serum (d)-β-OHB concentration achieved following 2 days starvation in man [14] and suggests that HM74a additionally mediates homeostatic negative feedback mechanisms to conserve fat stores during starvation [13].

A common side-effect of niacin administration is an intense prostaglandin-mediated skin flush due to vasodilation following release of prostaglandins PGD2 and PGE2 from resident dermal macrophages and/or epidermal cells [15], [16]. PGD2 is non-enzymatically dehydrated to form 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), the most potent endogenous ligand of peroxisome proliferator-activated receptor γ (PPARγ) [17]. Using the human differentiated monocytic cell line MonoMac6, it has been shown that niacin induces PPARγ expression and intracellular cAMP in monocytic cells, although the receptor(s) mediating this effect was not identified [18]. Niacin also enhanced transcription of both the oxidised LDL (oxLDL) scavenger receptor CD36 and of ABCA1, the key transporter for efflux of cellular cholesterol onto apolipoprotein A-I-containing HDL particles [18]. Niacin-induced effects on macrophage lipid regulation could present an additional mechanism whereby clinical administration of niacin might elevate HDL cholesterol levels and also reduce macrophage foam cell formation in atherogenesis [18], [8].

We have identified HM74 as a hypoxia-inducible gene from cDNA array analysis of normoxic and hypoxic monocytic cell lines. Interestingly, nicotinamide, the downstream conversion product of nicotinic acid and other prinicipal form of Vitamin B3, is central to the ARCON (accelerated radiotherapy with carbogen and nicotinamide) therapeutic strategy to overcome radiotherapy resistance due to hypoxia [19]. Nicotinamide operates by reducing intermittent vascular shut-down [20] to decrease perfusion-limited tumour hypoxia [21], in analogy to the effects of niacin on vascular parameters to increase local blood flow [15], [16]. Niacin and nicotinamide also have protective effects versus chemical and UV-induced carcinogenesis via a number of mechanisms including impaired immune surveillance [22], [23]. HM74 might therefore provide insight into mechanism(s) of vasodilation and a link between treatments for cancer and dyslipidaemia.

We have considered whether the receptor(s) mediating macrophage responses to niacin could be HM74a and/or HM74. We have determined that HM74 and HM74a mRNA is hypoxia-inducible in human monocytic cell lines and monocyte-derived macrophages. Additionally, we show that activation of both HM74 and HM74a by niacin stimulates the prostaglandin synthesis pathway resulting in elevated expression of PPARγ and enhanced PPARγ-dependent transcription activation. This demonstrates for the first time the effect of activation of the HM74 and HM74a GPCRs on macrophage gene expression and suggests an additional mechanism whereby HM74 and HM74a could mediate the clinical effects of niacin.

Section snippets

Cell culture

Cell lines were obtained from the Cancer Research UK cell service unless otherwise stated. Human monocytic cell lines THP1 (acute monocytic leukaemia) and U937 (lymphoma), 1397 and JB EBV-transformed lymphocytes (a gift from Dr. S. Holbrook, Weatherall Institute of Molecular Medicine, Oxford, UK), Jurkat (T cell acute lymphatic leukaemia), breast cancer cell lines MDA-MB-468 and MDA-MB-231, PC3 (prostate) and 293T (embryonic kidney) cells were maintained in RPMI 1640. HCT116 and HT29 (colon),

HM74 and HM74a are hypoxia-inducible in monocytic cells

We originally identified HM74 as a gene of interest in PMA-differentiated [25], [26] THP1 macrophages where, by cDNA array analysis, HM74 mRNA was upregulated 2.3-fold following 16 h hypoxic exposure (0.1% O2, data not shown). Ribonuclease protection assay (RPA) confirmed that hypoxic upregulation of HM74 mRNA was specific to PMA-treated cells in THP1 and U937 monocytic cell lines (Fig. 1A, top panel). As HM74 is also expressed in lymphocytes [2], we assayed 1397 and JB EBV-transformed

Discussion

The identification of HM74 and HM74a as niacin receptors has provided opportunity to determine the molecular mechanism(s) of niacin's clinical effects. It has recently been shown that niacin stimulates PPARγ- and cAMP-dependent mechanisms of reverse cholesterol transport in macrophages [18]. Our data now demonstrates that human macrophage cell lines and primary cells in culture express both HM74 and HM74a and that these receptors can directly mediate macrophage responses to niacin via

Acknowledgements

The authors are grateful to Prof. Peter J. Ratcliffe for many helpful discussions and to Cancer Research UK for funding.

References (64)

  • J.H.A.M. Kaanders et al.

    ARCON: a novel biology-based approach in radiotherapy

    Lancet Oncol

    (2002)
  • H. Vosper et al.

    The peroxisome proliferators-activated receptor delta promotes lipid accumulation in human macrophages

    J Biol Chem

    (2001)
  • P. Tontonoz et al.

    PPARγ promotes monocyte/macrophage differentiation and uptake of oxidised LDL

    Cell

    (1998)
  • A. Lorenzen et al.

    G-protein-coupled receptor for nicotinic acid in mouse macrophages

    Biochem Pharmacol

    (2002)
  • A. Elbrecht et al.

    Molecular cloning, expression and characterisation of human peroxisome proliferators activated receptors gamma 1 and gamma 2

    Biochem Biophys Res Commun

    (1996)
  • C. Grommes et al.

    Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists

    Lancet Oncol

    (2004)
  • J.S. Kerley et al.

    Transcriptional activation of the nuclear receptor corepressor RIP140 by retinoic acid: a potential negative-feedback regulatory mechanism

    Biochem Biophys Res Commun

    (2001)
  • M. Yi et al.

    Role of CBP/p300 and SRC-1 in transcriptional regulation of the pulmonary surfactant protein-A (SP_A) gene by thyroid transcription factor-1 (TTF-1)

    J Biol Chem

    (2002)
  • A. Clayton et al.

    Interleukin-1β differentially regulates β2 adrenoreceptor and prostaglandin E2-mediated cAMP accumulation and chloride efflux from Calu-3 bronchial epithelial cells

    J Biol Chem

    (2005)
  • L. Nagy et al.

    Oxidised LDL regulates macrophage gene expression through ligand activation of PPARγ

    Cell

    (1998)
  • S. Tunaru et al.

    PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

    Nat Med

    (2003)
  • A. Schaub et al.

    PUMA-G, an IFNγ-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily

    Eur J Immunol

    (2001)
  • C. Zellner et al.

    Variations in human HM74 (GPR109B) and HM74A (GPR109A) niacin receptors

    Hum Mutat

    (2005)
  • N.B. Pike et al.

    Identification of a nicotinic acid receptor: is this the molecular target for the oldest lipid-lowering drug?

    Curr Opin Invest Drugs

    (2004)
  • A.M. Gotto

    Management of dyslipidemia

    Am J Med

    (2002)
  • B. Senior et al.

    Direct regulatory effect of ketones on lipolysis and on glucose concentrations in man

    Nature

    (1968)
  • M.W. Bates et al.

    Blood D-3-hydroxybutarate and the regulation of plasma concentrations of free fatty acids in the fasted rat

    Metabolism

    (1976)
  • L. Laffel

    Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes

    Diab Metab Res Rev

    (1999)
  • D.J. Chaplin et al.

    Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumour

    J Natl Cancer Inst

    (1990)
  • M.R. Horsman et al.

    Tumour radiosensitisation by nicotinamide: a result of improved perfusion and oxygenation

    Radiat Res

    (1989)
  • H.L. Gensler et al.

    Oral niacin prevents photocarcinogenesis and photoimmunosuppression in mice

    Nutr Cancer

    (1999)
  • J.B. Kirkland

    Niacin and carcinogenesis

    Nutr Cancer

    (2003)
  • Cited by (86)

    • The Promise of Niacin in Neurology

      2023, Neurotherapeutics
    • Expression and activation of the ketone body receptor HCAR2/GPR109A promotes preservation of retinal endothelial cell barrier function

      2022, Experimental Eye Research
      Citation Excerpt :

      Quantification of images was done in ImageJ 1.51j8 (U. S. National Institutes of Health, Bethesda, MD). HCAR2/GPR109A expression has been reported in a diverse number of cell types (Martin et al., 2013; Knowles et al., 2006; Taggart et al., 2005). Anatomical profiling of GPCRs in human tissues revealed the possible association of HCAR2/GPR109A expression with three discrete tissue/cell-type clusters: barrier tissues, adipose tissues and immune cells (Regard et al., 2008).

    • Mitochondrial dysfunction in metabolic disorders

      2021, Mitochondrial Dysfunction and Nanotherapeutics: Aging, Diseases, and Nanotechnology-Related Strategies in Mitochondrial Medicine
    View all citing articles on Scopus
    View full text